These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 5166218)

  • 1. Sensitivity studies of L-dopa metabolites in reserpinized rats and their clinical significance.
    Ericsson AD; Wertman BG
    Neurology; 1971 Nov; 21(11):1129-33. PubMed ID: 5166218
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of the reserpine syndrome with L-dopa metabolites in reserpinized rats.
    Ericsson AD; Wertman BG; Duffy KM
    Neurology; 1971 Oct; 21(10):1023-9. PubMed ID: 5165302
    [No Abstract]   [Full Text] [Related]  

  • 3. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 4. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 5. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors.
    Ericsson AD
    J Neurol Sci; 1971 Oct; 14(2):193-7. PubMed ID: 5112212
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 7. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 8. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
    Hornykiewicz OD
    Neurology; 1970 Dec; 20(12):1-5. PubMed ID: 5531292
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 10. A simple and rapid gas chromatography for determining 3,4-dihydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid in urine from patients with parkinsonism treated with L-3,4-dihydroxyphenylalanine.
    Fukaya J; Imai K; Tamura Z
    Clin Chim Acta; 1971 Jul; 33(2):470-2. PubMed ID: 5119325
    [No Abstract]   [Full Text] [Related]  

  • 11. L-dopa in senile dementia.
    Van Woert MH; Heninger G; Rathey U; Bowers MB
    Lancet; 1970 Mar; 1(7646):573-4. PubMed ID: 4190401
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 14. Observations on the efficacy of L-dopa in progressive supranuclear palsy.
    Klawans HL; Ringel SP
    Eur Neurol; 1971; 5(2):115-29. PubMed ID: 5117103
    [No Abstract]   [Full Text] [Related]  

  • 15. [Abnormal movements induced by L-Dopa and dopamine metabolism disorders].
    Lhermitte F; Rosa A; Comoy E; Bohuon C
    Rev Neurol (Paris); 1973 Dec; 129(6):313-24. PubMed ID: 4794176
    [No Abstract]   [Full Text] [Related]  

  • 16. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
    Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
    Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 18. L-Dopa in the treatment of parkinsonism.
    Calne DB
    Clin Pharmacol Ther; 1970; 11(6):789-801. PubMed ID: 4921292
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 20. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.